Introducing MCC-PS: a novel prognostic score for Merkel cell carcinoma.

Area of Science:

• Oncology
• Dermatology
• Medical Diagnostics

Background:

• Merkel cell carcinoma (MCC) is an aggressive skin cancer with a historically poor prognosis.
• Existing immunotherapies have improved outcomes, but a highly accurate predictive model for MCC is still needed.

Purpose of the Study:

• To develop and validate a Merkel cell carcinoma prognostic score (MCC-PS) using readily available clinical and laboratory data.
• To identify key risk factors for predicting MCC patient outcomes.

Main Methods:

• A retrospective study involving 98 MCC patients was conducted.
• Data collected included age, neuron-specific enolase (NSE), C-reactive protein (CRP), and components of the Model for End-Stage Liver Disease (MELD) score (creatinine, bilirubin, INR).
• Statistical analyses included correlation, Kaplan-Meier curves, Cox regression, and time-dependent ROC analysis to develop and assess the MCC-PS.

Main Results:

• The MCC-PS incorporates elevated CRP (≥5.5 mg/l), elevated NSE (≥22.8 µg/l), MELD score (≥11), and age (≥75 years).
• A score of 4 or more identified a high-risk group with significantly worse 5-year MCC-specific survival (17.6%) compared to the low-risk group (72%).
• The MCC-PS demonstrated high accuracy in predicting outcomes, with a 5-year MCC-specific survival AUC of 0.93.

Conclusions:

• The MCC-PS is the first prognostic score for MCC that accurately predicts outcomes using easily accessible laboratory parameters and patient age.
• An MCC-PS of 4 or more effectively identifies patients with a high risk of poor prognosis, aiding clinical decision-making.